NASDAQ:CAMP CAMP4 Therapeutics (CAMP) Stock Price, News & Analysis $4.09 -0.11 (-2.62%) Closing price 04:00 PM EasternExtended Trading$4.13 +0.04 (+0.98%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About CAMP4 Therapeutics Stock (NASDAQ:CAMP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get CAMP4 Therapeutics alerts:Sign Up Key Stats Today's Range$3.98▼$4.3050-Day Range$3.14▼$4.6952-Week Range$2.90▼$7.75Volume62,418 shsAverage Volume201,207 shsMarket Capitalization$256.66 millionP/E RatioN/ADividend YieldN/APrice Target$10.44Consensus RatingModerate Buy Company Overview CAMP4 Therapeutics is a clinical-stage biotechnology company developing RNA-based medicines for genetic diseases in which the body produces too little of an essential protein. The company’s research focuses on increasing the expression of selected genes to address these protein deficiencies. Its Regulatory Action on RNA (RAP) platform is designed to identify regulatory RNAs that influence gene expression. CAMP4 uses antisense oligonucleotides to target these RNAs, with the goal of adjusting the activity of disease-related genes. Founded in 2016 and headquartered in Cambridge, Massachusetts, CAMP4 is focused on research and clinical development; its medicines are investigational and are not approved for commercial use.AI Generated. May Contain Errors. Read More CAMP4 Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreCAMP MarketRank™: 3.285229202035 of 5 starsCAMP4 Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 284th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingCAMP4 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialCAMP4 Therapeutics has a consensus price target of $10.44, representing about 157.3% upside from its current price of $4.06.Amount of Analyst CoverageCAMP4 Therapeutics has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about CAMP4 Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for CAMP4 Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CAMP4 Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CAMP4 Therapeutics is -1.89, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCAMP4 Therapeutics has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.63% of the float of CAMP4 Therapeutics has been sold short.Short Interest Ratio / Days to CoverCAMP4 Therapeutics has a short interest ratio ("days to cover") of 23.66, which indicates bearish sentiment.Change versus previous monthShort interest in CAMP4 Therapeutics has recently decreased by 5.56%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCAMP4 Therapeutics does not currently pay a dividend.Dividend GrowthCAMP4 Therapeutics does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.35 News SentimentCAMP4 Therapeutics has a news sentiment score of -0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 8 news articles for CAMP4 Therapeutics this week, compared to 3 articles on an average week.Search Interest3 people have searched for CAMP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CAMP4 Therapeutics insiders have sold 6,223.33% more of their company's stock than they have bought. Specifically, they have bought $39,600.00 in company stock and sold $2,504,037.00 in company stock.Percentage Held by Insiders21.69% of the stock of CAMP4 Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsCAMP4 Therapeutics has minimal institutional ownership at this time.Read more about CAMP4 Therapeutics' insider trading history. Receive CAMP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CAMP4 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CAMP Stock News HeadlinesCAMP4 Therapeutics (NASDAQ:CAMP) Share Price Breaks Above Fifty Day Moving Average on Disappointing EarningsNovember 8, 2026 | americanbankingnews.comCAMP4 Reports Third Quarter 2026 Financial Results and Corporate HighlightsNovember 5, 2026 | finance.yahoo.comWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.November 12 at 1:00 AM | Base Camp Trading (Ad)CAMP4 Shares Rise After EU Clinical Trial Application ApprovalsOctober 27, 2026 | marketwatch.comCAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European UnionOctober 27, 2026 | globenewswire.comRaymond James initiates coverage of Camp4 Therapeutics with strong buyOctober 23, 2026 | msn.comNeedham & Co Initiates Coverage on CAMP4 Therapeutics With Buy Rating, $8 Price TargetOctober 15, 2026 | marketscreener.comMCAMP4 to Participate in Chardan’s 10th Annual Healthcare ConferenceOctober 14, 2026 | markets.businessinsider.comSee More Headlines CAMP Stock Analysis - Frequently Asked Questions How have CAMP shares performed this year? CAMP4 Therapeutics' stock was trading at $6.0850 on January 1st, 2026. Since then, CAMP shares have decreased by 33.3% and is now trading at $4.06. How were CAMP4 Therapeutics' earnings last quarter? CAMP4 Therapeutics Corporation (NASDAQ:CAMP) released its quarterly earnings data on Thursday, November, 5th. The Wireless communications provider reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by $0.17. The Wireless communications provider had revenue of $1.90 million for the quarter. CAMP4 Therapeutics had a negative trailing twelve-month return on equity of 182.39% and a negative net margin of 2,276.33%. When did CAMP4 Therapeutics' stock split? Shares of CAMP4 Therapeutics reverse split on the morning of Friday, February 2nd 2024.The 1-23 reverse split was announced on Friday, February 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. Does CAMP4 Therapeutics have any subsidiaries? CAMP4 Therapeutics subsidiaries include these companies: LoJack, Gulfstream Telematics, SmartLink Radio Networks, CalAmp Wireless Networks Inc., Skybility, Boisen S.A., CalAmp Importation and Leasing of Tracking Equipment Ltd., and more. When did CAMP4 Therapeutics IPO? CAMP4 Therapeutics (CAMP) raised $102 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 6,820,000 shares at a price of $14.00-$16.00 per share. Who are CAMP4 Therapeutics' major shareholders? CAMP4 Therapeutics' top institutional shareholders include State Street Corp (0.89%) and Landscape Capital Management L.L.C. (0.10%). Insiders that own company stock include 5Am Partners Vi, Llc, Amir Nashat, Polaris Management Co Vii, L, Andrew J Schwab, Josh Mandel-Brehm, Richard A Young, Yuri Maricich, Kelly Gold, Jason Cohenour and Daniel Tardiff. View institutional ownership trends. How do I buy shares of CAMP4 Therapeutics? Shares of CAMP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CAMP4 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that CAMP4 Therapeutics investors own include Inseego (INSG), Union Pacific (UNP), Intel (INTC), Zimmer Biomet (ZBH), Tesla (TSLA), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/05/2026Today11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 CAMP's financial health is in the Green zone, according to TradeSmith. CAMP has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:CAMP CIK1736730 Webwww.camp4tx.com Phone(617) 651-8867Fax805-856-3857Employees48Year Founded1981Price Target and Rating Average Price Target for CAMP4 Therapeutics$10.44 High Price Target$15.00 Low Price Target$6.00 Potential Upside/Downside+155.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($2.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.40 million Net Margins-2,276.33% Pretax Margin-2,276.33% Return on Equity-182.39% Return on Assets-74.87% Debt Debt-to-Equity RatioN/A Current Ratio6.42 Quick Ratio6.42 Sales & Book Value Annual Sales$5.32 million Price / Sales48.25 Cash FlowN/A Price / Cash FlowN/A Book Value$1.71 per share Price / Book2.39Miscellaneous Outstanding Shares62,754,000Free Float49,143,000Market Cap$256.66 million OptionableNo Data Beta0.28 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:CAMP) was last updated on 11/12/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredMany investors are about to lose everythingTwenty five years ago, this analyst predicted the fiber optic boom and called Amazon before it became a househ...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredElon wants to move AI off the planet. Amazon isn't ready.What if the next AI race isn't on Earth? Tim Bohen's Mission X presentation explores Elon Musk's idea of movin...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CAMP4 Therapeutics Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share CAMP4 Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
